非洲审判新型HIV疫苗候选人开始

2021年8月05日

在赞比亚(CFHRZ)家庭健康研究中心提供的第一份剂量,在赞比亚卢萨卡,该试验将在未来的几周内延伸到肯尼亚和乌干达的地点.DR。William Kilembe, project director of CFHRZ and trial principal investigator, said: ‘International partnerships are crucial in developing and evaluating HIV vaccine candidates in countries and communities where HIV vaccines will ultimately have the greatest public health impact.While most HIV vaccine candidates work by inducing antibodies generated by B-cells, HIVconsvX induces the immune system’s potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable regions of HIV – an “Achilles heel” common to most HIV variants.Dr. Vincent Muturi-Kioi, medical director at IAVI, said: ‘It is crucial that we have a diverse pipeline of HIV vaccine candidates that target both the antibody and T-cell arms of the immune system.‘This is why it remains a priority that we design and evaluate novel vaccine approaches such as HIVconsvX.’The researchers hope to be able to report results of the HIV-CORE 006 trial at the end of 2022.

这个消息的来源来自牛津大学